DE60233061D1 - Alphavirus replikon-vektorsysteme - Google Patents

Alphavirus replikon-vektorsysteme

Info

Publication number
DE60233061D1
DE60233061D1 DE60233061T DE60233061T DE60233061D1 DE 60233061 D1 DE60233061 D1 DE 60233061D1 DE 60233061 T DE60233061 T DE 60233061T DE 60233061 T DE60233061 T DE 60233061T DE 60233061 D1 DE60233061 D1 DE 60233061D1
Authority
DE
Germany
Prior art keywords
replication
alphavirus replicon
vector systems
replicon vector
alphavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233061T
Other languages
English (en)
Inventor
Jonathan F Smith
Kurt I Kamrud
Jonathan O Rayner
Sergey A Dryga
Ian J Caley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphavax Inc
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23234980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60233061(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alphavax Inc filed Critical Alphavax Inc
Application granted granted Critical
Publication of DE60233061D1 publication Critical patent/DE60233061D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60233061T 2001-09-06 2002-09-06 Alphavirus replikon-vektorsysteme Expired - Lifetime DE60233061D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31772201P 2001-09-06 2001-09-06
PCT/US2002/028610 WO2003023026A1 (en) 2001-09-06 2002-09-06 Alphavirus replicon vector systems

Publications (1)

Publication Number Publication Date
DE60233061D1 true DE60233061D1 (de) 2009-09-03

Family

ID=23234980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233061T Expired - Lifetime DE60233061D1 (de) 2001-09-06 2002-09-06 Alphavirus replikon-vektorsysteme

Country Status (9)

Country Link
US (2) US7045335B2 (de)
EP (1) EP1432791B2 (de)
JP (1) JP4790984B2 (de)
AT (1) ATE437222T1 (de)
AU (1) AU2002327614B2 (de)
CA (1) CA2460269C (de)
DE (1) DE60233061D1 (de)
ES (1) ES2330202T5 (de)
WO (1) WO2003023026A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0019745D0 (en) * 2000-08-10 2000-09-27 Univ Surrey Gene expression element
JP4790984B2 (ja) 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP3184539A3 (de) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antikörper
EP1585812B1 (de) 2002-12-13 2017-01-18 Alphavax, Inc. Multiantigene alphavirusrepliconpartikel und verfahren
ES2630222T3 (es) 2002-12-13 2017-08-18 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
MXPA05010007A (es) * 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
EP1651666B1 (de) 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US20050257277A1 (en) * 2004-05-17 2005-11-17 Xiaobin Lu Regulation of transcription with a cis-acting ribozyme
PT1751289E (pt) * 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
CA2567446C (en) 2004-05-21 2018-01-02 Chiron Corporation Alphavirus vectors for respiratory pathogen vaccines
PT1751290E (pt) * 2004-05-25 2015-02-03 Novartis Vaccines & Diagnostic Construções de empacotamento de replicão de alfa vírus
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
US7332322B2 (en) * 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
WO2007002793A2 (en) * 2005-06-29 2007-01-04 The Board Of Regents Of The University Of Texas System Chimeric sindbis-eastern equine encephalitis virus and uses thereof
ES2746960T3 (es) 2006-09-12 2020-03-09 Alphavax Inc Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
NZ575901A (en) 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
ES2637629T3 (es) * 2006-11-09 2017-10-13 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
US8748591B2 (en) * 2007-04-17 2014-06-10 The Board Of Regents Of The University Of Texas System Chimeric sindbis-western equine encephalitis virus and uses thereof
ES2588906T3 (es) 2007-06-21 2016-11-07 Alphavax, Inc. Casetes sin promotor para la expresión de proteínas estructurales de alfavirus
WO2009042794A2 (en) * 2007-09-26 2009-04-02 Vanderbilt University Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
US20110229969A1 (en) * 2008-06-25 2011-09-22 Volker Sandig Cell Line for Propagation of Highly Attenuated AlphaViruses
WO2010040023A2 (en) 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
WO2010065414A1 (en) * 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
WO2010118244A1 (en) 2009-04-08 2010-10-14 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
WO2011130125A1 (en) * 2010-04-12 2011-10-20 Viracine Therapeutics Corporation Expression of positive sense single stranded rna virus and uses thereof
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
MX2013000164A (es) 2010-07-06 2013-03-05 Novartis Ag Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
EP2590670B1 (de) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Methoden zur auslösung einer immunantwort durch verabreichung von rna
WO2012006376A2 (en) * 2010-07-06 2012-01-12 Novartis Ag Virion-like delivery particles for self-replicating rna molecules
RS63984B1 (sr) * 2010-08-31 2023-03-31 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
HRP20220695T1 (hr) 2010-08-31 2022-07-08 Glaxosmithkline Biologicals Sa Pegilirani liposomi za isporuku rnk kodirane za imunogen
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
EP2632486A1 (de) 2010-10-27 2013-09-04 Harrisvaccines Inc Verfahren zur schnellen herstellung von impfstoffen für tiere
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
EP2729165B1 (de) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
AR089440A1 (es) * 2011-12-21 2014-08-20 Apse Llc Procesos que emplean particulas similares a virus (psv) con capsides resistentes a hidrolasas
EP3663395A1 (de) 2012-03-26 2020-06-10 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Verabreichung von verkapselter rna an säugerzellen
CA2873964A1 (en) 2012-05-21 2013-11-28 Steven F. Dowdy Generation of human ips cells by a synthetic self-replicative rna
BR112015009300A2 (pt) 2012-10-23 2018-05-15 Harrisvaccines Inc método de produção de uma vacina para proteger um animal de um biotipo de um microrganismo, método de proteção de um animal de um biotipo de um microrganismo e vacina para proteger um animal de um biotipo de um microrganismo.
BR112015029559A2 (pt) 2013-06-19 2017-12-12 Apse Llc partícula similar a vírus, ácido nucleico e métodos para produzir rna de fita dupla e sirna, shrna, sshrna, 1shrna e mirna
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
KR102467982B1 (ko) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
EP3727468A4 (de) 2017-12-19 2021-09-22 Akouos, Inc. Aav-vermittelte abgabe von therapeutischen antikörpern an das innenohr
AU2018388071A1 (en) 2017-12-20 2020-07-09 Vlp Therapeutics, Inc. Alphavirus replicon particle
AU2019225251A1 (en) 2018-02-26 2020-10-15 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
AU2019315577A1 (en) * 2018-08-03 2021-03-25 Uab Research Foundation Methods and compositions for alphavirus vaccine
MX2021013163A (es) 2019-04-28 2022-02-21 Selecta Biosciences Inc Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
MX2021014566A (es) 2019-05-28 2022-03-22 Selecta Biosciences Inc Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral.
EP4007814A1 (de) 2019-07-26 2022-06-08 Akouos, Inc. Verfahren zur behandlung von hörverlust unter verwendung eines sekretierten zielproteins
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US11730799B2 (en) * 2019-10-18 2023-08-22 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
CN116134131A (zh) 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
AU2021241355A1 (en) 2020-03-23 2022-10-13 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4165194A2 (de) 2020-05-13 2023-04-19 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von kcnq4-assoziiertem gehörverlust
IL298128A (en) 2020-05-13 2023-01-01 Akouos Inc Compositions and methods for treating slc26a4-associated hearing loss
JP2023551533A (ja) 2020-12-01 2023-12-08 アコーオス インコーポレイテッド 前庭神経鞘腫関連症状を治療するための抗ｖｅｇｆ抗体構築物及び関連する方法
EP4271419A1 (de) 2020-12-29 2023-11-08 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von clrn1-assoziiertem hörverlust und/oder sehverlust
IL311572A (en) 2021-09-30 2024-05-01 Akouos Inc Compositions and methods for treating KCNQ4-related hearing loss
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023220693A1 (en) 2022-05-12 2023-11-16 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2024009280A1 (en) 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
RU2057377C1 (ru) 1993-08-23 1996-03-27 Уральский электрохимический комбинат Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE437942T1 (de) 1993-09-15 2009-08-15 Novartis Vaccines & Diagnostic Rekombinante alphavirus-vektoren
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
JPH11504802A (ja) * 1994-11-30 1999-05-11 カイロン コーポレイション 組換えアルファウイルスベクター
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU2809897A (en) * 1996-04-23 1997-11-12 Wistar Institute Of Anatomy And Biology, The Novel human cytomegalovirus dna constructs and uses therefor
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CA2258158A1 (fr) * 1996-07-01 1998-01-08 Francis Blanche Procede de production d'adenovirus recombinants
JP2965908B2 (ja) 1996-07-05 1999-10-18 株式会社精工技研 調温液体シール手段を備える光ディスク成形用金型装置
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) * 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB9716611D0 (en) 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
DE69927249T2 (de) * 1998-03-27 2006-06-29 Cytos Biotechnology Ag Induzierendes alphavirengen- expressionssystem
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
EP1069908B1 (de) 1998-04-08 2010-02-10 The University of North Carolina at Chapel Hill Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
CA2336554A1 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
CA2336587A1 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
CA2345440A1 (en) * 1998-10-05 2000-04-13 Charles A. Nicolette Genes differentially expressed in cancer cells to design cancer vaccines
WO2000039318A1 (en) 1998-12-31 2000-07-06 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
EP1141313A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
DE60044125D1 (de) 1999-04-14 2010-05-20 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme
US6495743B1 (en) * 1999-06-28 2002-12-17 University Of Hawaii Plant xylanases
ATE412763T1 (de) 1999-08-31 2008-11-15 Univ North Carolina Antikörper-abhängige vergrösserung der alphavirus-infektvität
DE60135983D1 (de) * 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
WO2002003917A2 (en) 2000-07-07 2002-01-17 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
JP3544925B2 (ja) * 2000-07-27 2004-07-21 株式会社東芝 番組予約機能を備えた放送受信システムとその放送受信装置及び番組予約端末
AU2002227506A1 (en) 2000-07-28 2002-02-13 Visteon Global Technologies, Inc. An air intake arrangement for an internal combustion engine
AU9322201A (en) * 2000-08-29 2002-03-13 American Cyanamid Co Packaging of positive-strand rna virus replicon particles
AU2001290642A1 (en) * 2000-09-07 2002-03-22 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6800289B2 (en) * 2000-12-21 2004-10-05 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Strain of the western equine encephalitis virus
DE60239317D1 (de) 2001-01-12 2011-04-14 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
EP1399183B1 (de) * 2001-05-31 2010-06-30 Novartis Vaccines and Diagnostics, Inc. Chimere alphavirus-replikon-partikel
JP4790984B2 (ja) 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
WO2003083065A2 (en) 2002-03-25 2003-10-09 University Of North Carolina At Chapel Hill Improved methods for achieving expression from alphavirus vectors
JP3857195B2 (ja) * 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
WO2004043399A2 (en) * 2002-11-13 2004-05-27 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
EP1585812B1 (de) 2002-12-13 2017-01-18 Alphavax, Inc. Multiantigene alphavirusrepliconpartikel und verfahren
ES2630222T3 (es) 2002-12-13 2017-08-18 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
MXPA05010007A (es) 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
EP1651666B1 (de) * 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren

Also Published As

Publication number Publication date
ES2330202T3 (es) 2009-12-07
CA2460269C (en) 2013-01-15
JP4790984B2 (ja) 2011-10-12
EP1432791B1 (de) 2009-07-22
JP2005508159A (ja) 2005-03-31
EP1432791A1 (de) 2004-06-30
ATE437222T1 (de) 2009-08-15
US7425337B2 (en) 2008-09-16
EP1432791B2 (de) 2013-10-23
US7045335B2 (en) 2006-05-16
ES2330202T5 (es) 2014-01-20
US20060177819A1 (en) 2006-08-10
US20030119182A1 (en) 2003-06-26
CA2460269A1 (en) 2003-03-20
AU2002327614B2 (en) 2007-12-06
WO2003023026A1 (en) 2003-03-20
EP1432791A4 (de) 2005-07-27

Similar Documents

Publication Publication Date Title
ATE437222T1 (de) Alphavirus replikon-vektorsysteme
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
ATE466932T1 (de) Vermehrung von viren in zellkultur
SG149003A1 (en) Gene expression technique
ATE432285T1 (de) Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
ATE547511T1 (de) Nichttumorbildende mdck-zellinie zur vermehrung von viren
ATE481494T1 (de) Von rna viren abgeleitetes pflanzenexpressionssystem aus zwei komponenten
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
MXPA04003969A (es) Sistema de expresion de acido nucleico regulado.
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
BR0308736A (pt) Células de pulmão de rato cotton para cultura de vìrus
DE122011100041I1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren.
DE60334097D1 (de) Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen
DK1664087T3 (da) Fjernelse af prioner ved anvendelse af metaloxidpartikler
EP1309342A4 (de) Herstellung eines chimeren papillomavirus(22.01.2)
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
WO2002079482A3 (en) In vitro transcribed retroviral genomes, methods for their production and methods of use
ITMI991408A0 (it) Processo per la produzione di virus in colture cellulari

Legal Events

Date Code Title Description
8363 Opposition against the patent